CellRapeutics™ pan-ErbB-targeted Combination CAR-T Cell Engineering Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Potential of Targeting ErbB Family Cancer Therapy

CAR-T Immunotherapy has achieved unprecedented response rates in B-cell malignancies and myeloma patients. While the application of CAR-T therapy in solid tumors is not satisfactory. The lack of cancer-specific antigens, poor trafficking and penetration of CAR-T cells into malignant sites, and tumor microenvironment have led to this challenge. Currently, a wide range of target antigens are being studied for solid tumor therapy, and the ErbB family serves as a rich source of antigen candidates based on a variety of characteristics including prevalence, immunogenicity, and specificity.

Fig.1 TME hurdles in CAR-T Cell Immune Therapy for Solid Tumors.¹

Our CellRapeutics™ pan-ErbB-targeted Combination CAR-T cell Engineering Service

To address these issues, Creative Biolabs provides a robust and effective pan-ErbB-targeted combination CAR-T cell engineering service to speed up global customers' solid research. The pan-ErbB-targeted combination CAR-T strategy incorporates the promiscuous ErbB ligand T1E, placed upstream of a second-generation CAR design with a chimeric cytokine receptor (CCR). This approach could simultaneously direct T-cells specifically target all ErbB1 homo- and heterodimers, the ErbB 2/3 heterodimer, and all ErbB4 homo- and heterodimers expressing tumor cells with potent cytotoxic activity against a broad range of tumor types, decreasing the risk of immune evasion. Powered by our years of experience in the CAR-T field, we provide a one-stop pan-ErbB-targeted combination CAR-T cell engineering service, including from CAR design & construction, to function validation to speed up customers' solid research.

Fig.2 Schematic of pan-ErbB-targeted combination CAR-T cell engineering. (Creative Biolabs)

The Highlight of Our CellRapeutics™ pan-ErbB-targeted Combination CAR-T cell Engineering Service

Customized CAR Design & Construction
Creative Biolabs provides customized CAR design & construction strategies for global customers to satisfy variable needs.

Competent research team
Our research team has years of professional experience, which combined with advanced technologies makes us confident in providing high-quality data to global customers.

pan-ErbB-targeted Combination CAR-T cell Engineering Service

One-stop services
We provide a one-stop pan-ErbB-targeted combination CAR-T cell engineering services from CAR design to function validation.

Reliable and reputable experiment systems
Together with straightforward experimental procedures, we have complete confidence that we will achieve desirable outcomes for global customers.

Q1: What are the safety & challenges considerations for ErbB-targeted CARs?

A1: Several criteria need to be taken into account:

The persistence and migration of CAR-T cells to tumor sites for all ErbB-targeted CARs.
The risk of on-target, off-tumor toxicity owing to the recognition of the ErbB family on normal tissue.
The cytokine release syndrome (CRS) serves as a common side effect of CAR-T immunotherapy and is associated with an increase in inflammatory cytokines, such as IFN-γ and IL6.

Work with Creative Biolabs

In vivo efficacy and specificity validation of anti-TRBC1 CAR-T cells in T cell malignancy mouse model.

If you are interested in our CellRapeutics™ pan-ErbB-targeted combination CAR-T cell engineering service, please don't hesitate to contact us. Our experienced scientists try our best to meet the most challenging requirements and deliver the best answer for global customer satisfaction.

Reference

Boccalatte, F.; et al. Advances and Hurdles in CAR-T Cell Immune Therapy for Solid Tumors. Cancers. 2022; 14(20):5108.